Cullinan Therapeutics, Inc.
CGEM
$12.71
-$0.42-3.20%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 0.43% | 12.76% | 17.77% | 24.98% | 27.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.71% | 28.87% | 28.04% | 22.26% | 3.29% |
| Operating Income | -22.71% | -28.87% | -28.04% | -22.26% | -3.29% |
| Income Before Tax | -31.30% | -35.76% | -30.59% | -20.35% | 1.04% |
| Income Tax Expenses | -- | 100.83% | 100.83% | 100.83% | 100.83% |
| Earnings from Continuing Operations | -31.21% | -49.02% | -43.47% | -33.09% | -8.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -100.00% | -100.00% | -100.00% | -90.10% |
| Net Income | -31.36% | -51.05% | -45.44% | -35.05% | -9.28% |
| EBIT | -22.71% | -28.87% | -28.04% | -22.26% | -3.29% |
| EBITDA | -22.75% | -28.91% | -28.09% | -22.31% | -3.30% |
| EPS Basic | -18.75% | -27.86% | -13.52% | 1.51% | 15.34% |
| Normalized Basic EPS | -18.93% | -15.63% | -3.67% | 9.96% | 21.66% |
| EPS Diluted | -18.75% | -27.86% | -13.52% | 1.51% | 15.34% |
| Normalized Diluted EPS | -18.93% | -15.63% | -3.67% | 9.96% | 21.66% |
| Average Basic Shares Outstanding | -17.67% | 18.26% | 27.91% | 37.02% | 29.38% |
| Average Diluted Shares Outstanding | 9.81% | 18.26% | 27.91% | 37.02% | 29.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |